Latest news with #DPI
Yahoo
4 days ago
- Business
- Yahoo
Nob Hill Therapeutics Expands Strategic Advisory Board with Two Distinguished Leaders in Respiratory Drug Development and Pulmonary Medicine
ALBUQUERQUE, N.M., June 18, 2025 /PRNewswire/ -- Nob Hill Therapeutics (NHT) is pleased to announce the addition of two prominent experts to its Strategic Advisory Board: Dr. Mark Parry-Billings, a seasoned biotech and pharmaceutical executive with extensive experience in respiratory drug development and Dr. Scott L. Shofer, a physician-scientist and critical care specialist affiliated with Duke University Hospital with deep expertise in pulmonary and interstitial lung disease. These appointments underscore NHT's commitment to advancing its mission of transforming the treatment landscape for serious lung diseases through targeted pulmonary delivery of advanced therapeutics. NHT's proprietary DryNeb dry powder inhaler (DPI) platform is designed to enable the efficient delivery of high doses of medicine directly to the lungs. The DryNeb can work with a broad range of therapeutics and allows a patient to breath normally while using the DPI platform. Dr. Mark Parry-Billings, PhD is a biotech and pharmaceutical executive with an international track record of more than 30 years in leadership and senior R&D roles. Most recently, he served as Global Head of Drug Development at Chiesi (a global pharmaceutical company with a significant commitment to respiratory medicine). Prior to this, he served as CEO of Topigen Pharmaceuticals (a clinical stage biotech with gene silencing inhaled therapeutics), and has worked for pSivida (a NASDAQ-listed drug delivery company) and Innovata Biomed (a company focused on dry powder inhaler technology). He is Chairman of the Board of Directors at Synairgen. His expertise will be instrumental in shaping NHT's development strategy and navigating the complex path from preclinical innovation to clinical and commercial success. Dr. Scott L. Shofer, MD, PhD is a critical care physician and pulmonologist with over 20 years of experience, including specialized work in obstructive and interstitial lung disease. He completed his medical degree at Boston University School of Medicine and went on to train at Stanford and Duke University, where he is currently affiliated. Dr. Shofer has led and contributed to numerous clinical trials and published extensively in peer-reviewed journals. His deep clinical insight and commitment to evidence-based care will help guide the company's clinical development and ensure alignment with real-world patient needs. "We are honored to welcome Dr. Parry-Billings and Dr. Shofer to our Strategic Advisory Board," said Noel Greenberger, CEO of Nob Hill Therapeutics. "Their combined expertise in respiratory drug development and clinical pulmonary medicine adds tremendous strength to our team as we advance our inhaled pipeline." With these new appointments, Nob Hill Therapeutics continues to build a world-class team of advisors who bring critical insight across drug development, device innovation, and clinical implementation, all essential to achieving its vision of delivering high-impact therapies directly to the lungs. For more information, please visit – Pioneering Respiratory Patient Care Nob Hill Therapeutics is a VIC Technology Venture Development portfolio company. About VIC Technology Venture Development, LLC VIC Technology Venture Development creates innovative new companies with world-changing science- and engineering-based technologies. VIC carefully selects and licenses technologies from universities and research institutions worldwide, then partners technology entrepreneurs with VIC's business and technology experts and allocates seed capital through the national VIC Investor Network. In addition, VIC provides its portfolio companies with senior management expertise, extensive knowledge of technology startups, and proven processes to execute business strategies, including legal, financial, operations, marketing, capital acquisition, and technology management. For more information, please visit Contact Information: Noel Greenberger, NHT CEO View original content to download multimedia: SOURCE Nob Hill Therapeutics
Hindustan Times
4 days ago
- Business
- Hindustan Times
New schemes on the anvil under Haryana startup policy
The Haryana government is planning to launch a new set of schemes aimed at providing comprehensive financial and infrastructural assistance to government-owned, government-supported and private incubators under the Haryana State Startup Policy 2022. This was stated during a review meeting of the State Startup Ecosystem and Incubator Schemes held under the chairmanship of chief secretary Anurag Rastogi on Tuesday. Commissioner and secretary, industries and commerce, Amit Agrawal on Tuesday said that the schemes included capital subsidy covering 50% of the capital expenditure, up to ₹2 crore for government host institutions and ₹1 crore for private ones. 'Financial assistance of up to ₹4 crore will be available for the development of new startup warehouses or innovation campuses with an additional ₹1 crore per annum for three years to meet recurring operating expenses. A similar support structure is planned for the creation of Mobile Application Development Centres,' Agarwal said. To further ease the operational burden, the schemes offer a 50% reimbursement on lease rent (up to ₹5 lakh per year for three years) and 100% reimbursement on stamp duty and registration charges. Government-owned or supported incubators will also receive ₹2.5 lakh annually for mentorship initiatives, he said. 'Additionally, financial support of up to ₹50 lakh per event will be provided for organising or participating in national and international exhibitions and startup fairs.' Agrawal said that the state has made significant strides in the field of innovation and entrepreneurship, emerging as the seventh-largest state in the country in terms of the number of startups recognised with the Department for Promotion of Industry and Internal Trade (DPIIT). 'With over 8,800 DPI IT-recognised startups, the state reflects a vibrant and growing startup ecosystem that is contributing to economic diversification and job creation,'' he added. The state has also built a strong incubation infrastructure to support startups at various stages. 'Over 25 incubators have been established in government and private universities across the state. Additionally, over 10 private-sector-run incubators and 10 government-supported incubators are currently operational, offering a wide range of services including mentorship, networking opportunities and infrastructural support,' Agaral said. 'Several institutions have expressed interest in setting up new incubation centers, which will further strengthen the support system for early-stage startups. Over 45% of the startups in Haryana are led by women entrepreneurs,' he added.
Business Standard
5 days ago
- Business
- Business Standard
Lupin inks licensing deal with Sino Universal pharma for Tiotropium DPI drug in China
Lupin announced that it has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI) capsules in China for the treatment of chronic obstructive pulmonary disease. As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing the product. Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions. Fabrice Egros, president of corporate development, Lupin, said, "We are very pleased to partner with SUP to bring Tiotropium DPI to patients in China. This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector. SUP is our esteemed partner in this endeavor, and together we aim to enhance patient access to innovative and high-quality healthcare solutions. Wang Li, president of SUP, said, "We are truly honored to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip rose 0.05% to Rs 2,001.45 on the BSE.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Lupin, Sino Universal sign agreement to launch Tiotropium DPI in China
Lupin Limited on Monday entered into a licence and supply agreement with Sino Universal Pharmaceuticals (SUP) to launch Tiotropium Dry Powder Inhaler (DPI), 18 mcg per capsule, in the Chinese market, according to a BSE filing by the company. Tiotropium DPI is used to treat chronic obstructive pulmonary disease (COPD). As part of the agreement, SUP will be responsible for securing regulatory approvals in China to sell the Tiotropium DPI. Meanwhile, Lupin will hold the marketing authorisation and manage the product's manufacturing. Focus on COPD treatment and access Tiotropium DPI is recognised for its ability to help patients with respiratory diseases by improving lung function and quality of life. This partnership supports Lupin's efforts to widen its reach in China, ensuring people have timely access to effective and reliable healthcare treatments, particularly as respiratory illnesses rise. Wang Li, President of SUP, added, "We are truly honoured to partner with Lupin, a global pharmaceutical leader, on Tiotropium DPI. Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care. By bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health." Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical company focused on a wide range of products, including branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients. Sino Universal Pharmaceuticals, based in China, is a global one-stop pharmaceutical distribution and management service provider with over 18 years of experience.
Time of India
6 days ago
- Politics
- Time of India
Chhattisgarh teachers begin protest against rationalisation, govt claims 80% drop in single-teacher schools
Chhattisgarh Shikshak Sanjha Manch is protesting against the state's teacher rationalisation policy, alleging the removal of 46,000 teaching posts RAIPUR: The Chhattisgarh Shikshak Sanjha Manch (CSSM) has launched a statewide protest against the state government's teacher rationalisation policy, alleging the removal of over 46,000 teaching posts. The agitation began on Monday with black armband demonstrations and parent outreach, and will culminate in a major protest on Teachers' Day, 5 September. The CSSM, a joint forum of teachers, announced an intensified agitation against the state's rationalisation policy following a review meeting on 14 June. State convener Virendra Dubey said the forum is planning a structured protest, including a large-scale demonstration on Teachers' Day . On Monday, as schools reopened after the summer vacation, teachers across Chhattisgarh wore black armbands to protest against the policy. The forum urged all teachers in the state to participate in the upcoming protests. The plan includes the following stages: 16–30 June: Teachers will wear black armbands to mark their protest. 16–20 June: Members of the forum will reach out to parents, informing them about the flaws in the rationalisation process and the alleged reduction in teaching positions, seeking their support. Affected teachers will submit applications to the Directorate of Public Instruction (DPI) and the Education Secretary, either in person or by post. Copies will be shared with block, district, divisional, or state conveners. 20 June: Applications will be sent to the Chief Justice of India by affected teachers. 30 June: Demand letters will be sent to the Prime Minister by forum office-bearers and affected teachers. A memorandum detailing the discrepancies will be submitted to the DPI and the Education Secretary. 1 July: Teachers will go on a one-day strike and stage protests at 146 block headquarters across the state. 5 September: A major state-level protest will be held on Teachers' Day. Govt Claims Rationalisation Boosted School Staffing Meanwhile, the Chhattisgarh government has defended the rationalisation move, stating it has improved teacher deployment across the state. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trading CFD dengan Teknologi dan Kecepatan Lebih Baik IC Markets Mendaftar Undo According to the government, the number of single-teacher schools has been reduced by 80%, and no school is left without staff, particularly in remote areas. A government spokesperson said the transformation was possible due to rationalisation, which focused on equitable distribution of resources, logical teacher deployment, and postings in line with the Right to Education Act and the New Education Policy. Previously, 453 schools in the state had no teachers, and 5,936 schools had only one teacher. This problem was especially serious in remote and sensitive districts like Sukma, Narayanpur, and Bijapur. To address the issue, a three-phase counselling process was held at the district, divisional, and state levels. As a result, all high schools now have the minimum required teaching staff, and no school is left without a teacher. Chief minister Vishnu Deo Sai has said that improving single-teacher schools is a key government priority. Additional teachers will be appointed through promotions and new recruitments in the coming months. The state is now focusing on 1,207 primary schools that still have only one teacher. Plans are in place to prioritise promotions, postings, and recruitment to improve staffing. Of these schools, Bastar has 283, Bijapur 250, Sukma 186, Mohla-Manpur-Chowki 124, Korba 89, Balrampur 94, Narayanpur 64, Dhamtari 37, Surajpur 47, Dantewada 11, while other districts have a total of 22 such schools. The government said teachers will be deployed to these schools based on need.
